At a glance
- Originator Fujisawa
- Class Small molecules
- Mechanism of Action Adenosine triphosphatase inhibitors; Proton pump inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 17 Apr 2000 New profile
- 17 Apr 2000 Preclinical development for Postmenopausal osteoporosis in Japan (Unknown route)